Physician profile
John Adams
NPI 1477629129
$6,558.23
in general payments reported to CMS, 2019-2025
27 companies · $2,345 in 2025
The $2,345 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $204 · 2021: $897 · 2022: $666 · 2023: $886 · 2024: $1,060 · 2025: $2,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,197 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,197.00 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,067.43 | 2019-2025 | Biktarvy |
| Janssen Biotech, INC. | $967.26 | 2019-2025 | Tremfya |
| Viiv Healthcare Company | $947.64 | 2022-2025 | Apretude |
| Regeneron Healthcare Solutions, INC. | $391.37 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $388.07 | 2020-2025 | Mounjaro, Zepbound, Taltz |
| Arcutis Biotherapeutics, INC. | $255.09 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $225.74 | 2023-2025 | Winlevi, Absorica Ld |
| Leo Pharma INC. | $178.24 | 2021-2025 | Anzupgo, Adbry |
| Amgen INC. | $175.12 | 2023-2024 | Otezla |
| Incyte Corporation | $128.24 | 2024-2025 | Opzelura |
| Abbvie INC. | $126.33 | 2024 | |
| Mayne Pharma Commercial LLC | $119.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $81.03 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.29 | 2021 | |
| Novo Nordisk INC | $79.26 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $67.82 | 2025 | Korlym |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $46.60 | 2025 | Cabtreo, Siliq, Jublia |
| Galderma Laboratories, L.P. | $42.85 | 2019-2025 | |
| Almirall LLC | $39.13 | 2020-2025 | Seysara |
| Napo Pharmaceuticals INC | $32.37 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $22.79 | 2024 | |
| Shire North American Group INC | $22.67 | 2019 | |
| Biofrontera INC. | $20.15 | 2022 | |
| Genentech USA, INC. | $19.98 | 2020 | |
| Genzyme Corporation | $17.78 | 2021 | |
| Journey Medical Corporation | $15.46 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.